(16.11.2022) The corporate economic situation, with its combination of increasingly volatile markets and a skilled workforce that is constantly concerned with work-life balance, is driving SMEs to hire interim managers.
(02.11.2022) Parliament has instructed the Federal Council to draft federal law on the review of foreign investments. Eric Scheidegger, Head of SECO's Economic Policy Directorate and Deputy Director, provides an update on this initiative.
(05.10.2022) Mainly used for crypto-currencies, blockchain is also being implemented elsewhere and the movement does not seem to be slowing down any time soon. Faced with strong international competition in the sector, what are Switzerland's competitive advantages? Emilie Raffo, co-founder of the company ChainSecurity and expert in the field, provides the answers.
(21.09.2022) The international organization Ashoka supports social entrepreneurship projects around the world. Emilie Romon Carnegie, its director in Switzerland, discusses the key drivers and challenges in this field.
(07.09.2022) After two difficult years, the events sector has regained some momentum. Gabriele Censi, Director of GC Events, has relied on digitalization and innovative exhibitions to get through the pandemic. He reflects on the industry's challenges and opportunities for renewal.
(17.08.2022) The Société Suisse de crédit hôtelier (SCH), which is co-financed by the Confederation, provides financial support and consulting services to hotels. Its director, Peter Gloor, explains the role and function of the organization.
(19.07.2022) Angel investment can make all the difference in getting a start-up off the ground. But what kind of people and projects are business angels looking for? Brigitte Baumann, an expert in the field, explains.
(06.07.2022) The franchise business model is relatively unknown in Switzerland. Marc Haesler, director of Swiss Distribution, the franchisors' association in French-speaking Switzerland, provides some insights into this type of business.
(01.06.2022) In just ten years, the Max Zeller Söhne company has grown from twelve to thirty export markets. With 150 employees, the firm specializes in the production of phytotherapeutic drugs. A market leader in Switzerland, it has also succeeded in establishing itself in many Asian and Eastern European countries.